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Background: Neurological abnormalities including a variety of subtle deficits such as dis-
crete impairments in sensory integration, motor coordination (MOCO), and sequencing of
complex motor acts are frequently found in patients with schizophrenia (SZ) and commonly
referred to as neurological soft signs (NSS). Asperger-syndrome (AS) is characterized by
sensory-motor difficulties as well. However, the question whether the two disorders share
a common or a disease-specific pattern of NSS remains unresolved.
Method: A total of 78 age- and education-matched participants [26 patients with recent-
onset SZ, 26 individuals with AS, and 26 healthy controls (HC)] were recruited for the study.
Analyses of covariance (ANCOVAs), with age, years of education, and medication included
as covariates, were used to examine group differences on total NSS and the five subscale
scores. Discriminant analyses were employed to identify the NSS subscales that maximally
discriminate between the three groups.
Results: Significant differences among the three groups were found in NSS total score and
on the five NSS subscales. The clinical groups differed significantly in the NSS subscale
MOCO. The correct discriminant rate between patients with SZ and individuals with AS
was 61.5%.The correct discriminant rate was 92.3% between individuals with AS and HC,
and 80.8% between SZ patients and HC, respectively.
Conclusion: Our findings provide new evidence for the presence of NSS in AS and lend
further support to previously reported difficulties in movement control in this disorder.
According to the present results, SZ and AS seem to be characterized by both quantitative
and qualitative NSS expression.
Keywords: NSS, motor abnormalities, recent-onset schizophrenia, Asperger-syndrome
INTRODUCTION
Neurological soft signs (NSS) are neurological abnormalities
including a variety of subtle deficits such as discrete impairments
in sensory integration, motor coordination, sequencing of com-
plex motor acts, clumsiness, and occurrence of primitive reflexes
(1–3). A higher prevalence of NSS has been consistently demon-
strated not only in patients with clinically manifest schizophrenia
(SZ) but also in their non-psychotic first-degree relatives (4).
Recent studies indicated that NSS are not only restricted to SZ
but are also present in bipolar disorders, depression, obsessive–
compulsive disorders (OCD), and other forms of psychosis (5).
Nevertheless, previous studies have assessed the power of NSS to
discriminate between SZ and other neuropsychiatric disorders. In
particular, SZ patients have significantly higher NSS levels than
individuals with OCD (6, 7), alcohol dependence (8), bipolar dis-
orders (9, 10), depression (11), and mixed psychiatric diagnoses
(12). From a neurobiological point of view, the prefix “soft” indi-
cates that NSS refer to a non-specific or global cerebral dysfunction
rather than to impairments of specific or distinct brain regions.
Recent magnetic resonance imaging (MRI) studies on SZ found
that increased NSS levels are related to aberrant brain morphol-
ogy within cortical (13–15) and subcortical regions (13, 16–20).
Furthermore, the aforementioned studies converge on the conclu-
sion that NSS should be discussed as potential endophenotypes
for SZ (4).
In 1911, a renowned German psychiatrist named Eugen Bleuler
introduced the concept of accessory and fundamental symptoms
in SZ (21, 22). Accessory symptoms were non-specific state phe-
nomena and comprised hallucinations, delusions, and catatonic
signs (21). The fundamental symptoms were more specific to
SZ and included autism, formal thought disorders, ambivalence,
disorders of volition, affective-emotional, and affect-expressive
changes (21, 22). Furthermore, when Bleuler (21) described the
“autistic core”in SZ patients, he spoke about the withdrawal within
the own inner world: “The most severe schizophrenics, who have no
more contact with the outside world live in a world of their own.
They have encased themselves with their desires and wishes [. . .];
they have cut themselves off as much as possible from any contact
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with the external world. This detachment from reality with the rel-
ative and absolute predominance of the inner life, we term autism”
[(21, 23), p. 1122]. In general, the schizophrenic autism is char-
acterized by a rich variety of clinical phenomena such as poor
ability to interact with others, inaccessibility, negativistic tenden-
cies, indifference, rigid attitudes, and behaviors, private hierarchy
of values and goals, inappropriate expression and behavior, and
idiosyncratic logic and thinking, respectively (22). Taken together,
from the historical standpoint, SZ, and autism have been regarded
as part of the same spectrum (24, 25).
In the early 40s, Kanner’s (26) and Asperger’s (27) use of the
term autism changed it in the direction of its present meaning
of disturbed social cognition. Subsequently, with the introduc-
tion of DSM-III in the late 1970s, autism became an independent
diagnostic entity not being part of the diagnostic concept of
SZ. However, problems with interpersonal contact, interaffective
attunement, and perspective-taking, are core to both patholo-
gies, though appearing in different forms, and hence, several
studies provided empirical evidence for a diagnostic overlap in
both disorders (28). Furthermore, clinical studies have shown that
negative/deficit, disorganized, and motor symptoms are present
in both individuals with autism and patients with SZ (29–31).
More recently, before introduction of DSM-5, some authors even
discussed an autism dimension for SZ (25). This suggests that dis-
tinguishing between both spectrum disorders remains a diagnostic
challenge. Such diagnostic overlaps might confound the diagnosis
and delay appropriate treatment of these patients. As a matter of
fact, the symptoms overlap could at least partially account for the
inconsistent findings in previous scientific studies.
Asperger-syndrome (AS) belongs to pervasive developmental
disorders and is characterized by interaction and communication
difficulties, and repetitive, stereotype, and restricted patterns of
behavior. In fact, several clinical studies observed motor abnormal-
ities in individuals with AS including involuntary dyskinesia, rigid-
ity, hypotonia, abnormal posture and gait, clumsiness, reduced
coordination of locomotor skills, and unstable balance, respec-
tively (32–35). Some authors even consider motor abnormalities
as a putative endophenotype for autism spectrum disorders (36).
In the last decade, clinical research interest on motor abnormalities
in autism has extended to the investigation of NSS in AS. However,
there are only two studies which have investigated NSS prevalence
in individuals diagnosed with AS (33, 34) and we are still lacking
a profound understanding of NSS in AS.
Overall, the above mentioned clinical studies suggest that motor
abnormalities are a typical characteristic of SZ and AS. Hence,
there is a stimulating debate whether these disorders share similar
sensory-motor features or not (37). Regarding subtle neurological
deficits in autism, however, only Mayoral et al. (34) compared NSS
in early-onset SZ and AS. Therefore, at present it is difficult to high-
light a potential difference in subtle sensory-motor abnormalities
in patients with SZ and individuals with AS. The precise evalua-
tion of subtle sensory-motor neurological signs in SZ and AS is of
potential clinical significance, since the assessment of NSS might
allow for more accurate disease classification. Also, this approach
might help to overcome the missing conceptual clarity and better
delineate a precise phenotype in order to identify endophenotypes
underpinning SZ and AS.
The purpose of this investigation was twofold. First, we were
interested in whether there is a difference between NSS severity
in patients with SZ and individuals with AS. Second, we sought
to identify characteristic NSS, which are either unique or shared
by both disorders. Based on the findings of a previous study in
juveniles (34) and on our clinical observation, it was hypothesized
that individuals with AS would show NSS scores at least as high
as patients with SZ. Further, we expected AS individuals being
predominantly susceptible to NSS that involve gross motor skills.
Finally, we employed a descriptive and predictive linear discrimi-
nation analysis (LDA) in order to examine if both total NSS and
subscale scores are able to discriminate between the three groups.
MATERIALS AND METHODS
SUBJECTS
The study sample consisted of 26 clinically stable patients with
recent-onset SZ, 26 individuals with AS, and 26 healthy controls
(HC) who participated in a larger study at the Department of Gen-
eral Psychiatry in Heidelberg, Germany as part of the Toward an
Embodied Science of Intersubjectivity-Project (TESIS). The study
sample was consecutively recruited between 2010 and 2013 from
the Department of General Psychiatry in Heidelberg, Germany
and from SALO GmbH in Ludwigshafen, Germany, a professional
rehabilitation institution of education for autistic individuals. All
participants were Caucasians. Study participants were excluded
if: (1) they were aged <18 or >35 years, (2) they had a history
of brain trauma or neurological disease, (3) they had a comor-
bid Axis-I- or -II-Disorder according to ICD-10 or DSM-IV, (4)
they had shown alcohol/substance abuse or dependence within
24 months prior to participation, or (5) they had an IQ< 70.
Diagnoses of SZ and AS were made by specialized clinicians (DH
and PAT) corresponding to DSM-IV criteria and supplemented
by an extensive neuropsychological assessment. Clinical symp-
tom determinations and structured clinical diagnostic interviews
were conducted by trained clinical raters (Dusan Hirjak, Laura
Mehl, and Janna K. Kelbel) and senior diagnosticians (Sabine C.
Koch, Philipp Arthur Thomann). In particular, all study individ-
uals were assessed for lifetime psychiatric diagnoses by trained
psychiatrists (Dusan Hirjak and Philipp Arthur Thomann) via the
German version of the Structured Clinical Interview for DSM-
IV (38) and reviews of hospital case notes. All participants in
the AS group had previously received a clinical diagnosis of AS
(F84.5) from an independent clinician according to standard cri-
teria (a valid diagnosis of autism is an admission criterion for
SALO GmbH). In addition, diagnoses of the participants with AS
were confirmed with the Autism Diagnostic Observation Schedule
[ADOS; (39)] administered by a trained and clinically experienced
psychiatrist (Dusan Hirjak). In addition, IQ of individuals with AS
(F84.5) has been systematically assessed with the German version
of the Culture Fair Intelligence Test (CFT-20-R) (40). The intel-
ligence in SZ patients and HC was not explicitly assessed, but
clinically judged to be average or above average. Both patients
with SZ and HC were required to have a leaving certificate from
one of the secondary schools – Hautpschule (9 years), Realschule
(10 years),or Gymnasium (13 years) – in order to participate in our
study. The demographics and psychiatric history of the two clini-
cal samples were retrieved from medical records. To examine the
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possible effect of medications on NSS, we standardized the dosage
of antipsychotic medications chlorpromazine equivalents (CPZ).
In healthy individuals, we used the PRIME early psychosis screen-
ing test [prevention through risk identification, management, and
education (PRIME)] to screen for the presence of early psychotic
symptoms, including information on any contact or treatment for
any mental or psychological disorder (41). All study participants
gave informed consent to participation, and the study has been
approved by the local ethics committee of the Medical Faculty,
University of Heidelberg, Germany.
CLINICAL ASSESSMENTS
Neurological soft signs were assessed using the Heidelberg Scale (2)
that consists of five items assessing motor coordination (MOCO)
(Ozeretski’s test, diadochokinesia, pronation/supination, finger-
to-thumb opposition, speech articulation), three items assessing
integrative functions (IF) (station and gait, tandem walking, two-
point discrimination), two items assessing complex motor tasks
(COMT) (finger-to-nose test, fist-edge-palm test), four items
assessing right/left and spatial orientation (RLSO) (right/left ori-
entation, graphesthesia, face-hand test, stereognosis), and two
items assessing hard signs (HS) (arm holding test, mirror move-
ments). Items were rated on a 0 (no prevalence) to 3 (marked
prevalence) point scale. All items, with the exception of station and
gait, tandem walking, right/left orientation, speech articulation,
primitive reflexes, and Ozeretzki’s test were rated separately on
the right and left side. A sufficient internal reliability (Cronbach’s
alpha 0.83) and high test-retest reliability (0.88) have been estab-
lished previously (2, 42). In the study conducted by Schröder and
colleagues (2), to test the interrater reliability of the NSS scale, 42
patients and HC were simultaneously evaluated by two raters. The
internal reliability of the scale was assessed by calculating Cron-
bach’s α. The testing procedure was generally standardized, but
the explanations and the time required to complete the tasks were
adjusted to the condition of the patients. In the present study, the
NSS assessment has been conducted by two raters (Janna K. Kelbel
and Laura Mehl) trained and supervised by the same psychiatrist
(Dusan Hirjak). Both raters were blind to the main hypothesis of
the study and investigated study participants independent of their
diagnosis. Handedness was assessed on the Edinburgh Inventory
(43). The severity of psychopathological symptoms was assessed
with the Brief Psychiatric Rating Scale (BPRS) (44), the Scale for
the Assessment of Positive Symptoms (SAPS) (45), and the Scale
for the Assessment of Negative Symptoms (SANS) (46). Predic-
tors of outcome were rated on the Strauss-Carpenter Scale (SCS)
(47). The social, occupational, and psychological functioning in
individuals with AS was assessed with the Global Assessment of
Functioning (GAF) scale (48).
CHARACTERISTICS OF PARTICIPANTS
The three groups of participants were matched according to age
and education. Level of IQ among individuals with AS ranged
from 71 to 124 (mean IQ: 99.0± 18.5) according to CFT-20-R
(40). Patients with SZ according to DSM-IV had an initial onset
of psychosis within 2 years prior to study entry with a mean
duration of illness of 7.15 months (range 2–15 months). SZ sub-
types were distributed as follows: paranoid n= 12, disorganized
n= 4, and undifferentiated n= 10. At the time of inclusion,
all SZ patients were clinically stable with consistent medica-
tion doses for 4 weeks or longer. They were receiving treatment
with a single second-generation antipsychotic agent according
to their psychiatrists’ choice. Patients were treated on average
for 2.33± 1.44 months throughout the course of illness. Poten-
tial extrapyramidal side effects were excluded before study entry
by an experienced psychiatrist who was not directly involved
in the study. Individuals with AS and HC did not take any
antipsychotic, mood stabilizing, anti-cholinergic, or antidepres-
sive medications. SZ patients had low or no prevalence of positive
and negative symptoms, as measured by SAPS (range: 0–74),
SANS (range: 0–70), and BPRS. At the time of clinical and NSS
assessment, no SZ patients manifested psychotic symptoms (two
or more of the positive symptom items >3 or a total SAPS
score >40).
DATA ANALYSIS
Data were analyzed using the Statistical Package of the Social
Sciences (SPSS version 21.0, SPSS Inc., Chicago, IL, USA). Sociode-
mographic and clinical variables were described and compared
between the three groups with unpaired t-test or chi-square test
for categorical variables using conventional significance levels
(p< 0.05). To test for differences in NSS performance between
the three study subgroups, we conducted an analysis of covariance
(ANCOVA) including the potentially distorting factors age, years
of education, and CPZ. Gender comparisons on NSS performance
within each study group and between the three groups used t-tests
and analysis of covariance (ANCOVA). Further, p values of the
identified NSS subscales were corrected for the number of tested
NSS subscales in our main analysis using the Bonferroni method.
To this end, α was set to p= 0.05/N, where n (=18) equaled the
number of correlations (classical Bonferroni correction). For this
reason, the corrected threshold was set to p= 0.0027 [α= 0.05/18
tests (total NSS+ five subscale scores× three groups)]. In a sec-
ond step, a series of ANCOVAs considering age, years of education,
and CPZ as covariates was conducted to further examine the dif-
ferences between groups if a significant main effect was identified.
Further, p values of the identified NSS subscales were corrected for
the number of tested NSS subscales using the Bonferroni method.
To this end, α was set to p= 0.05/N, where n (=12) equaled the
number of correlations (classical Bonferroni correction). For this
reason, the corrected threshold was set to p= 0.0041 [α= 0.05/12
tests (total NSS+ five subscale scores× two groups)]. Correlative
analyses of SAPS, SANS, BPRS, and CPZ with total scores and
subscores of NSS were conducted with the Pearson correlation
coefficient.
To examine the ability of NSS to discriminate among the three
groups, both descriptive and predictive LDAs were used (11, 49,
50). The aim of this analysis was to determine whether NSS sub-
scales would discriminate between patients with SZ and those
with AS. In this study, total NSS and the five subscale scores
were treated as “within subject variable” (independent variables),
whereas the diagnostic group was treated as the “between sub-
ject factor” (grouping variable). However, only those NSS scores
that reached statistical significance in the ANCOVAs were used as
predictive variables.
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RESULTS
Demographic characteristics of the patient groups and the HC are
summarized in Table 1. Comparison of the three groups revealed a
significant difference in gender (chi-square test: χ2= 8.35; df= 2;
p= 0.015) and CPZ [F(2, 75)= 85.16; p< 0.001]. There were no
significant differences in age [F(2, 75)= 0.55; p= 0.577] and years
of education [F(2, 75)= 2.63; p= 0.078] among the three groups.
There was also no significant difference for BPRS scores between
SZ patients and individuals with AS [F(1, 50)= 2.9; p= 0.094].
There were no significant differences between male and female par-
ticipants in NSS performance among the three groups. In addition,
we found no significant differences between male and female indi-
viduals in the control group in any of NSS scores (Table 3). But,
there was a significant gender difference in the performance on
NSS subscale COMT in both individuals with AS and SZ patients
(Table 3). However, this effect is most likely driven by the influence
of confounders such as age, education, and medication, since a sig-
nificant gender effect diminished after covarying for these factors.
GROUP DIFFERENCE IN NSS SCORES (ANCOVA: CONTROLLING FOR
AGE, YEARS OF EDUCATION, AND MEDICATION)
Table 1 shows the prevalence of NSS across the three groups. Sig-
nificant differences after controlling for age, years of education,
and CPZ were found in NSS total score [F(5, 72)= 14.7;p< 0.001]
and on the five NSS subscales MOCO [F(5, 72)= 11.5; p< 0.001],
IF [F(5, 72)= 3.41; p= 0.008], COMT [F(5, 72)= 8.9; p< 0.001],
RLSO [F(5, 72)= 4.02; p= 0.003] and HS [F(5, 72)= 3.2;
p= 0.012] among the three groups (Figure 1; Table 2). Fur-
ther, p values of the identified NSS subscales were corrected for
the number of tested NSS subscales in our main analysis using
the Bonferroni method (p< 0.0027). NSS total and two sub-
scale scores (MOCO and COMT) hold Bonferroni correction for
multiple testing.
AS VS. SZ
The ANCOVA showed that compared with SZ patients, the indi-
viduals with AS showed significantly higher NSS total scores
[F(4, 47)= 3.63; p= 0.012] and higher scores on the subscale
COMT [F(4, 47)= 4.2; p= 0.005]. However, individuals with AS
showed lower scores on the NSS subscale MOCO [F(4, 47)= 4.38;
p= 0.004] when compared to SZ patients. Further, p values of
the two identified NSS subscales were corrected for the number
of tested NSS subscales in our main analysis using the Bonferroni
method (p< 0.0041). Only the NSS subscale, MOCO hold Bon-
ferroni correction for multiple testing. No significant difference
was found between individuals with AS and SZ patients on the
Table 1 | Descriptive summary of the sociodemographic and clinical variables of all participants.
Variable Asperger-syndrome (n=26) Schizophrenia (n=26) Healthy controls (n=26)
Mean age, years (SD) 22.76±3.81 23.38±3.87 23.58±3.77
Gender, n
Male 18 (69.2%) 9 (34.7%) 9 (34.7%)
Female 8 (30.8%) 17 (65.3%) 17 (65.3%)
Handedness, n
Right 23 (88.4%) 26 (100%) 26 (100%)
Left 3 (11.6%) 0 (0%) 0 (0%)
Mean education, years (SD) 12.03±1.84 12.07±1.32 12.8±0.63
Mean duration of illness, months (SD) – 7.15± .31 –
Mean antipsychotic dose(CPZ) (SD) 0 435.11±240.4 0
Mean NSS score (SD) 16.19±6.71 (median=14.5) 14.92±7.54 (median=16.0) 5.57±3.08 (median=5.5)
MOCO 6.23±3.31 6.79±3.91 2.11±1.55
IF 2.61±1.62 1.92±1.38 1.42±1.06
COMT 2.84±1.68 1.61±1.67 0.61±0.89
RLSO 3.07±2.41 1.65±1.89 0.8±1.05
HS 1.42±1.65 1.73±1.34 0.61±0.89
Mean ADOSa (SD) 13.61±3.27 – –
Mean SAPSb (SD) – 20.11±13.98 –
Mean SANSc (SD) 41.07±15.78 30.69±18.81 –
Mean BPRSd (SD) 29.34±15.49 23.0±10.94 –
Mean SCSe (SD) – 39.0±15.72 –
Mean GAFf (SD) 63.96±10.67 – –
Mean± standard deviation (SD).
aAutism Diagnostic Observation Schedule.
bScale for the assessment of negative symptoms.
cScale for the assessment of positive symptoms.
dBrief Psychiatric Rating Scale.
eStrauss-Carpenter Scale.
fGlobal Assessment of Functioning.
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Table 2 | Group differences in NSS performance.
NSS measure AS vs. SZ vs. HC AS vs. SZ AS vs. HC SZ vs. HC
F (5, 72) p F (4, 47) p F (3, 48) p F (4, 47) p
NSS total score 14.7 <0.001 3.63 0.012 24.5 <0.001 12.9 <0.001
MOCO 11.5 <0.001 4.38 0.004 15.29 <0.001 11.33 <0.001
COMT 8.9 <0.001 4.2 0.005 17.81 <0.001 2.45 0.059
IF 3.41 0.008 2.51 0.054 3.71 0.018 2.59 0.048
RLSO 4.02 0.003 1.5 0.217 6.21 0.001 1.56 0.2
HS 3.2 0.012 1.1 0.364 3.25 0.03 4.48 0.004
ANCOVA= controlling for age, years of education and medication (CPZ); MOCO, motor coordination; COMT, complex motor tasks; IF, integrative function; RLSO,
right/left and spatial orientation; HS, hard signs; AS, Asperger-syndrome; SZ, schizophrenia patients; HC, healthy controls. Differences surviving Bonferroni correction
in bold.
Table 3 | Gender differences in NSS performance (two-tailed t -tests).
NSS measures Asperger-syndrome Schizophrenia Healthy controls
Male
(n=18)
Female
(n=8)
t
(df=24)
p Male
(n=9)
Female
(n=17)
t
(df=24)
p Male
(n=9)
Female
(n=17)
t
(df=24)
p
NSS total score 16.5±6.86 15.5±6.76 −0.34 0.73 11.66±7.77 16.64±7.04 1.65 0.11 5.88±3.10 5.41±3.16 −0.36 0.71
MOCO 6.55±3.72 5.5±2.13 −0.74 0.46 5.44±4.15 7.47±3.71 1.27 0.21 2.11±1.69 2.11±1.53 0.01 0.99
COMT 3.27±1.70 1.87±1.14 −2.08 0.04 0.66±1.65 2.11±1.49 2.26 0.03 0.66±1.0 0.58±087 −0.2 0.83
IF 2.50±1.72 2.87±1.45 0.53 0.59 1.55±1.01 2.11±1.53 0.98 0.33 1.66±1.11 1.29±1.04 −0.84 0.40
RLSO 2.77±1.80 3.75±3.49 0.94 0.35 1.44±1.87 1.76±1.95 0.4 0.69 0.55±0.88 0.94±1.14 0.87 0.38
HS 1.38±1.81 1.50±1.30 0.15 0.87 1.33±1.0 1.94±1.47 1.1 0.28 0.88±1.16 0.47±0.71 −1.13 0.26
Mean±SD; MOCO, motor coordination; COMT, complex motor tasks; IF, integrative function; RLSO, right/left and spatial orientation; HS, hard. Bold font indicates
significant differences (p<0.05).
FIGURE 1 | Neurological soft signs total scores and NSS scores
on the five subscales among the three groups. The bottom and top
of the box represent the first and third quartile, and the band inside
the box is the second quartile (the median). The ends of the whiskers
indicate the minimum and maximum of the NSS performance.
MOCO, motor coordination; COMT, complex motor tasks; IF,
integrative functions; RLSO, right/left and spatial orientation; HS, hard
signs.
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subscales IF [F(4, 47)= 2.51; p= 0.054], RLSO [F(4, 47)= 1.5;
p= 0.217], and HS [F(4, 47)= 1.1; p= 0.364].
AS VS. HC
Compared with HC, individuals with AS showed significantly
higher NSS total scores [F(3, 48)= 24.50; p< 0.001] and elevated
NSS on the subscales MOCO [F(3, 48)= 15.29; p< 0.001], IF
[F(3, 48)= 3.71; p= 0.018], COMT [F(3, 48)= 17.81; p< 0.001],
RLSO [F(3, 48)= 6.21; p= 0.001], and HS [F(3, 48)= 3.25;
p= 0.03]. NSS total and three subscale scores (MOCO, COMT,
and RLSO) hold Bonferroni correction for multiple testing
(p< 0.0041).
SZ VS. HC
Compared with HC, SZ patients showed significantly more total
NSS signs [F(4, 47)= 12.90; p< 0.001] and higher NSS scores
on the subscale MOCO [F(4, 47)= 11.33; p< 0.001], IF [F(4,
47)= 2.59; p= 0.048], and HS [F(4, 47)= 4.48; p= 0.004]. NSS
total and two subscale scores (MOCO and HS) hold Bonferroni
correction for multiple testing (p< 0.0041). Additionally, no sig-
nificant difference was found between SZ patients and HC on
the subscale COMT [F(4, 47)= 2.45; p= 0.059] and RLSO [F(4,
47)= 1.56; p= 0.2].
CLINICAL COMPARISONS
In patients with SZ, SAPS, SANS, and BPRS scores were not signif-
icantly associated with total score and five subscores of NSS at the
conventional significance level (p< 0.05). In individuals with AS,
BPRS scores were not associated with total score and five subscores
of NSS at the conventional significance level (p< 0.05).
DISCRIMINANT ANALYSES OF NSS PERFORMANCE
In this study, we conducted a LDA (11, 49, 50), to examine the
ability of the total NSS and five subscale scores to discriminate
between the three groups. With this method, we also tested for
the possibility of predicting the correct diagnosis solely based on
NSS performance. Only the NSS subscales that reached statisti-
cal significance in post hoc analysis and survived the Bonferroni
correction were used as predictive variables.
Using predictive LDA, we found that 71.8% of the cases were
correctly classified in terms of the group as a function of the total
NSS and two subscale scores (MOCO and COMT). The individ-
ual discriminant rates for each diagnostic group were 92.3% for
HC, 69.2% for individuals with AS, and 53.8% for SZ patients.
The results of the descriptive LDA revealed the emergence of
two significant linear discriminant functions: function 1 (Wilks’
λ= 0.495; χ2= 52.106; p< 0.001; eigenvalue: 0.627; canonical
correlation= 0.621) could explain 72.1% of the variance, while
function 2 (Wilks’ λ= 0.805; χ2= 16.084; p< 0.001; eigenvalue:
0.243; canonical correlation= 0.442) could only explain 27.9% of
the variance. The distribution of the three groups is shown in
Figure 2 and function 1 and function 2 are illustrated.
In this study, predictive LDA was also conducted for group–
group comparison. All three analyses showed significant results.
AS VS. SZ
One of them was between individuals with AS and SZ patients. In
this analysis, only the NSS subscale MOCO that reached statistical
FIGURE 2 | Canonical discriminant functions of neurological soft signs
(total score, MOCO, and COMT), which are prevalence for patients
with AS, schizophrenia, and healthy controls. MOCO, motor
coordination; COMT, complex motor tasks.
significance in the post hoc analysis and survived the Bonfer-
roni correction was used as predictor variable. The total cor-
rect discriminant rate was 61.5%. The results of the descriptive
LDA revealed the emergence of non-significant linear discrim-
inant function (Wilks’ λ= 0.994; χ2= 0.283; p= 0.595; eigen-
value: 0.006; canonical correlation= 0.076). Because of the non-
significant discriminant function between individuals with AS and
patients with SZ, we re-ran the LDA by adding two more NSS
variables, which did not survive the Bonferroni correction (11).
After including the NSS total score and the NSS subscale COMT
in the LDA, the correct discriminant rate elevated from 61.5
to 71.2% (Wilks’ λ= 0.774; χ2= 12.438; p= 0.006; eigenvalue:
0.292; canonical correlation= 0.476). The correct rate of AS indi-
viduals was 65.4%, while the correct rate of SZ patients was 76.9%.
AS VS. HC
The other was between individuals with AS and HC. In this analy-
sis, total NSS and three subscale scores (MOCO, COMT, and HS)
that reached statistical significance in the post hoc analysis and sur-
vived the Bonferroni correction were used as predictor variables.
The total correct discriminant rate was 92.3%. The descriptive
LDA revealed the emergence of one significant linear discriminant
function (Wilks’ λ= 0.445; χ2= 37.746; p< 0.001; eigenvalue:
1.195; canonical correlation= 0.738).
SZ VS. HC
The remaining predictive LDA was between SZ patients and HC. In
this analysis, total NSS and three subscale scores (MOCO and HS)
that reached statistical significance in the post hoc analysis and sur-
vived the Bonferroni correction were used as predictor variables.
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The total correct discriminant rate was 80.8%. The results of the
descriptive LDA revealed the emergence of one significant linear
discriminant function (Wilks’ λ= 0.569; χ2= 27.334; p< 0.001;
eigenvalue: 0.757; canonical correlation= 0.656).
POTENTIAL INFLUENCE OF MEDICATION
In patients with SZ, NSS total scores (r = 0.335; p= 0.095) and
scores on the subscales MOCO (r = 0.262; p= 0.228), COMT
(r = 0.133; p= 0.547), HS (r = 0.255; p= 0.240), IF (r = 0.289;
p= 0.182), and RLSO (r = 0.140; p= 0.523) were not associ-
ated with CPZ equivalents at the conventional significance level
(p< 0.05).
DISCUSSION
This study assessed and compared NSS levels in both patients
with SZ and AS. Two main findings emerged: first, patients with
SZ show significantly higher NSS score on the subscale MOCO
when compared to individuals with AS. Second, SZ patients can
be distinguished from those with AS by only one NSS subscale
(MOCO). These findings were consistent across the analyses of
prevalence and in the LDA.
Previous studies on motor abnormalities in AS clearly under-
estimated the prevalence of NSS in this syndrome and focused
exclusively on rather complex movement disorders. In fact, only
two previous studies investigated the severity of NSS in AS (33,
34). In the study conducted by Tani (33), individuals with AS had
significantly higher NSS total and complex motor acts scores when
compared to the control group. The authors concluded that NSS
represent a non-specific vulnerability factor for AS (33). More
recently, Mayoral (34) investigated 30 patients with early-onset
SZ and 29 individuals with AS. In agreement with our results,
they found that individuals with AS have higher NSS scores than
HC. Second, however, the authors concluded that there are no
significant differences between both patient groups in any of the
NSS scores. However, it is possible that the discordant findings
reported by Mayoral (34) were due to large differences in socio-
demographic variables among the study participants. In fact, the
IQ levels in the control group were significantly higher than in
SZ patients and individuals with AS. Hence, some patients with
AS were taking antipsychotic medication, a fact that may have
biased particular NSS tasks in this group. Last but not least, recent
research indicates that only 5% of SZ patients have a psychosis
onset before age of 15 years (51). Therefore, investigating young
patients with early-onset SZ does not allow making inferences
for the whole SZ spectrum, because NSS might be instable in sub-
groups of young patients with incomplete brain maturation. Thus,
the above mentioned findings cannot be generalized to the whole
autism spectrum.
To some extent, our findings are consistent with the two above
mentioned NSS studies. In line with results presented by Tani
(33), we found that individuals with AS exhibit higher NSS lev-
els on the subscale MOCO, COMT, and RLSO when compared to
HC. However, we did not find any significant difference between
NSS levels on the subscale HS. In contrast to Mayoral (34),
who found no differences between SZ and patients with AS, we
observed significantly higher NSS scores on the subscale MOCO
in SZ when compared to individuals with AS. Compared with
both previous studies, our findings are likely to be more robust
because of three reasons: first, individuals with AS were free of
psychotropic medication. Though all our SZ patients were med-
icated, the negative results in correlations between NSS and CPZ
further reduces potential concerns that our findings might be
confounded by antipsychotic drug treatment. Furthermore, the
duration of exposure to second-generation antipsychotic medica-
tion in SZ patients was rather low. A second strength of our study
is that individuals with SZ and AS had low prevalence of acute psy-
chiatric symptoms and, in addition, did not differ in BPRS scores
as measures of psychopathology. We believe this to be important,
as SZ patients with more severe psychotic symptoms have been
shown to score higher on the NSS scale in comparison with SZ
patients without any negative or positive symptoms (3). In fact,
recent studies showed that patients with negative symptoms are
characterized by more severe neurological abnormalities includ-
ing different sensory-motor functions (52). For instance, a number
of reports have also noted that SZ patients with negative symptoms
exhibit higher prevalence of spontaneous movements (53, 54) or
NSS (55–59) . In conclusion, there is an association between NSS
and negative symptoms in SZ. However, our SZ sample scored
rather low on SANS and SAPS. Third, SZ patients and individuals
with AS were of similar educational level. Given the large body
of evidence in individuals with AS and SZ suggesting a significant
relationship between intelligence and movement (60), we used
years of education as a covariate when analyzing differences in
NSS scores. In contrast to both aforementioned studies, our study
sample comprised mainly young adults in a clinically stable dis-
ease state and rather advanced brain maturation. However, for the
interpretation of the present results, it is important to bear in mind
that the human brain undergoes a highly dynamic development,
which continues into adulthood (61). While the majority of lon-
gitudinal studies on brain growth in autism focused on children,
the trend of brain development in adolescence, and adulthood
remains unidentified (62). Our data might support the hypothesis
of developmental deficits in AS during adolescence and adulthood.
Several lines of scientific evidence suggest that AS and SZ have
both unique and similar sensory-motor features. In particular,
there is a stimulating debate whether these disorders are related
conditions or not (37). The findings of our present study pro-
vide support for both positions. SZ patients exhibited significantly
higher NSS levels on the subscale MOCO when compared to indi-
viduals with AS. The NSS subscale MOCO comprises both, tasks
which involve small muscles of the hand, and tasks which neces-
sitate a tight link between one’s own bodily movement and the
spatial–temporal constraints. This finding is of particular inter-
est given recent evidence of individuals with SZ showing poor
levels of motor dexterity (63). As such, this action is based on
visual perception and fine motor precision. Therefore, our first
finding supports the hypothesis that patients with SZ exhibit seri-
ous problems when using sensory information to guide and time
fine finger and hand movements. Moreover, there is some evi-
dence that abnormalities of fine MOCO have a developmental
origin and manifest even in a group of clinical at-risk mental state
individuals (64, 65). In fact, research on NSS in ultra-high risk
(UHR) conditions for developing mental illness might also provide
important clues for the understanding of motor abnormalities in
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psychotic disorders. Nevertheless, to date, only few studies inves-
tigated NSS in UHR individuals (66, 67). Leask and colleagues
(67) concluded that NSS might precede SZ, but are not caused by
infectious illness in early childhood. In the pioneer longitudinal
neuroimaging study on UHR individuals, Mittal and colleagues
(68) suggested a significant relationship between NSS and lon-
gitudinal cerebellar-thalamic tract integrity. As such, NSS might
provide insight into the role of cognitive dysmetria in the high-
risk period. These results are supported by previous research on
infant motor development that considered childhood neuromo-
tor dysfunction as a risk factor for SZ spectrum disorders (64,
69). In summary, NSS might be considered as an intrinsic part of
vulnerability to psychosis and should be discussed as markers of
disordered neurodevelopment in SZ (70).
After Bonferroni correction, no significant differences were
found between SZ and AS in total NSS and four subscales com-
prising rather gross motor skills such as stait and gait, tandem
walking, finger-to-nose test or right/left orientation. There are sev-
eral explanations for the particular deficit in gross motor skills in
both disorders. In order to properly perform gross bodily actions,
the interaction of motor cortex, basal ganglia, and thalamus is crit-
ical. Recently, altered gray matter volumes within the limbic basal
ganglia loop system (e.g., left thalamus, putamen) were found to
be common in both SZ and autism (37, 71). We believe that these
findings lend support to the theory of a disrupted basal ganglia
loop system in both disorders and suggest that SZ and AS share
a number of neurobiological similarities. Hence, our results pro-
vide arguments against the theory that SZ and AS are diametrically
opposite ends of a continuum (72).
The present study employed LDA in order to test for unique dis-
ease related patterns of NSS and to explore the degree of accuracy
to which these patterns could be used to statistically discriminate
between SZ and AS. Although the NSS subscale MOCO was found
to be the most important predictor involved in discriminating,
among the two clinical groups, it only accounted for an overall
61.5% correct classification. These results implicate that the level
of abnormalities in perception-action coupling as described by
MOCO may serve as a valuable predictor when trying to differen-
tiate between patients with SZ and AS. However, it is noteworthy
that by combining the NSS subscale MOCO with the total NSS
and COMT subscale score the correct discriminant rate elevated
to 71.2% and revealed significant discriminant function. Because
of our modest sample size, some findings diminished more than
it would have probably been the case with a larger study group.
Although the LDA consisting NSS total scores was significant, NSS
subscales tended to fall below our cut-off of 0.05 as the determi-
nant of significance. Still, our observation that the subscale MOCO
has a significant discriminant power between SZ patients and indi-
viduals with AS supports earlier assumptions that abnormalities of
motor dexterity per se might be a major characteristic of SZ (73).
According to our results, especially motor tests evaluating fine
motor skills and manual dexterity might be helpful when classify-
ing and differentiating patients with SZ and individuals with AS.
LIMITATIONS
We acknowledge several potential limitations of this study such as
the possible differences in IQ levels among the study participants.
It is thus possible that we missed small between-group effects due
to missing IQ scores in SZ patients and the control group. Apart
from this, deficits in global measures of cognition such as intelli-
gence are common in SZ patients (74, 75). On the other side, it
is a well-established finding that IQ levels do not change over the
course of illness and that lower IQ is a stable trait in patients suf-
fering from SZ (76–78). Furthermore, variables such as education,
occupation, and age can contribute significantly to IQ values (79).
In other words, we believe the recent evidence to clearly suggest
years of education as being an appropriate and stable indicator
of global cognition in SZ. Second, the relatively small number of
participants in each study group limits the power of the LDA.
Third, statistical analysis of the three groups revealed a significant
difference in gender. According to Cai (80) and colleagues, higher
NSS levels were observed in 14- and 15-years-old boys when com-
pared with girls of the same age. Since the differences in NSS
performance declined with increasing age, the authors concluded
that young boys might experience a delay of brain maturation
when compared to girls of similar age, and hence, this might cause
higher NSS scores in the male group (80). In our study, there were
no differences for age distribution among the three groups and the
majority of our study subjects were young adults with completed
brain maturation. Further, there were no significant differences
between male and female participants in NSS performance among
the three groups. Therefore, uneven gender distribution across
diagnostic groups might have not directly impact upon results
of the statistical analysis in this study. Fourth, all SZ patients
had been exposed to antipsychotic medication. In order to par-
tial out a putative dose-dependent effect of second-generation
antipsychotics on NSS performance, SZ patients’ CPZ were con-
sidered as potential confounders in the present study. Although
CPZ doses were included as covariates in the statistical analyses,
we cannot completely rule out the possibility that antipsychotic
medication might have influenced the NSS performance to some
degree. Still, an influence of medication in our study is unlikely as
every SZ patient was treated with atypical neuroleptics, the dura-
tion of treatment was relatively short, and none of the subjects
showed serious medication side effects. Furthermore, none of the
individuals with AS was treated with second- or first-generation
antipsychotics. Correspondingly, second-generation antipsychotic
treatment or medication side effects seem to have no effect on NSS
performance in SZ (81). Fifth, healthy participants were not explic-
itly screened for AS by means of a standardized test. However, no
signs of autistic traits were observed in healthy subjects during
clinical and diagnostic (DSM-IV) interviewing. Last but not least,
our study sample comprised patients suffering from different sub-
types of SZ, a point that might complicate the interpretation of
our results (82). However, subgroups were too small to test for this
potential influence. Moreover, it is important to bear in mind that
our findings are preliminary and that they need to be replicated in
larger samples.
CONCLUSION
Sensory-motor abnormalities in SZ and AS might manifest as NSS.
Since NSS are present in both, individuals with SZ and AS, they
may represent a putative neuromotor marker across the traditional
diagnostic categorization. Understanding the role of NSS could
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help to gain further insight into the neurobiological underpin-
nings of SZ and AS. To this end, future studies should ideally
combine thorough clinical, neurological, and psychopathological
assessments with multi-modal neuroimaging techniques in order
to elucidate how the respective factors relate to each other.
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